Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Noile-Immune Biotech Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥124.00 |
52 Week High | JP¥775.00 |
52 Week Low | JP¥123.00 |
Beta | 0 |
1 Month Change | -28.32% |
3 Month Change | -36.41% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -82.66% |
Recent News & Updates
Shareholder Returns
4893 | JP Biotechs | JP Market | |
---|---|---|---|
7D | -7.5% | 2.4% | 0.08% |
1Y | n/a | -22.2% | 25.1% |
Return vs Industry: Insufficient data to determine how 4893 performed against the JP Biotechs industry.
Return vs Market: Insufficient data to determine how 4893 performed against the JP Market.
Price Volatility
4893 volatility | |
---|---|
4893 Average Weekly Movement | 5.7% |
Biotechs Industry Average Movement | 7.2% |
Market Average Movement | 4.0% |
10% most volatile stocks in JP Market | 7.8% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4893's share price has been volatile over the past 3 months.
Volatility Over Time: 4893's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | 28 | Koji Tamada | www.noile-immune.com |
Noile-Immune Biotech Inc. researches and develops CAR-T cells for cancer immunotherapies. The company was incorporated in 2015 and is headquartered in Minato, Japan.
Noile-Immune Biotech Inc. Fundamentals Summary
4893 fundamental statistics | |
---|---|
Market cap | JP¥5.54b |
Earnings (TTM) | -JP¥976.00m |
Revenue (TTM) | JP¥310.00m |
17.3x
P/S Ratio-5.5x
P/E RatioIs 4893 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4893 income statement (TTM) | |
---|---|
Revenue | JP¥310.00m |
Cost of Revenue | JP¥41.00m |
Gross Profit | JP¥269.00m |
Other Expenses | JP¥1.25b |
Earnings | -JP¥976.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -22.54 |
Gross Margin | 86.77% |
Net Profit Margin | -314.84% |
Debt/Equity Ratio | 0% |
How did 4893 perform over the long term?
See historical performance and comparison